Doviner Victoria, Maly Bella, Kaplan Victoria, Gingis-Velitski Svetlana, Ilan Neta, Vlodavsky Israel, Sherman Yoav
Department of Pathology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Mod Pathol. 2006 Jun;19(6):878-88. doi: 10.1038/modpathol.3800603.
Heparanase is a mammalian endo-beta-D-glucuronidase that cleaves heparan sulfate side chains at a limited number of sites. Such enzymatic activity is thought to participate in degradation and remodeling of the extracellular matrix and to facilitate cell invasion associated with tumor metastasis, angiogenesis and inflammation. Traditionally, heparanase activity was well correlated with the metastatic potential of a large number of tumor-derived cell types. More recently, heparanase upregulation has been documented in an increasing number of primary human tumors, correlating with poor postoperative survival and increased tumor vascularity. Here, we employed anti-heparanase 733 polyclonal antibody that preferentially recognizes the 50 kDa active heparanase subunit over the 65 kDa proenzyme, as well as anti-heparanase 92.4 monoclonal antibody that recognizes both the latent and the active enzyme, to follow heparanase expression, processing and localization throughout the adenoma-carcinoma transition of the colon epithelium. Normal (nondysplastic) mucosa of the large bowel near epithelial neoplasms, as well as areas of mild dysplasia in adenomas, exhibited a strong reactivity with antibody 733 that became even stronger in foci of moderate dysplasia. Interestingly, although reactivity with antibody 733 was markedly reduced in severe dysplasia and in colorectal carcinoma, response to antibody 92.4 exhibited the opposite trend and staining intensities increased in parallel with tumor stage, the highest being in carcinoma cells. Involvement of latent heparanase (detected by 92.4, but not by 733 antibody) in tumor progression was suggested by activation of the Akt/PKB signal transduction pathway upon heparanase overexpression or exogenous addition to HT29 human colon carcinoma cells. These results suggest that heparanase expression is induced during colon carcinogenesis, and that its processing, conformation and localization are tightly regulated during the course of colon adenoma-carcinoma progression.
乙酰肝素酶是一种哺乳动物内切β-D-葡糖醛酸酶,可在有限数量的位点切割硫酸乙酰肝素侧链。这种酶活性被认为参与细胞外基质的降解和重塑,并促进与肿瘤转移、血管生成和炎症相关的细胞侵袭。传统上,乙酰肝素酶活性与大量肿瘤来源细胞类型的转移潜能密切相关。最近,越来越多的原发性人类肿瘤中记录到乙酰肝素酶上调,这与术后生存率低和肿瘤血管增多相关。在这里,我们使用了抗乙酰肝素酶733多克隆抗体,该抗体优先识别50 kDa的活性乙酰肝素酶亚基而非65 kDa的酶原,以及抗乙酰肝素酶92.4单克隆抗体,该抗体可识别潜伏和活性酶,以追踪结肠上皮腺瘤-癌转变过程中乙酰肝素酶的表达、加工和定位。上皮肿瘤附近大肠的正常(无发育异常)黏膜以及腺瘤中的轻度发育异常区域,与抗体733呈现强反应性,在中度发育异常灶中反应性更强。有趣的是,尽管在重度发育异常和结直肠癌中与抗体733的反应性明显降低,但对抗体92.4的反应呈现相反趋势,染色强度随肿瘤分期增加,在癌细胞中最高。乙酰肝素酶过表达或外源性添加到HT29人结肠癌细胞后,Akt/PKB信号转导通路的激活提示潜伏性乙酰肝素酶(由92.4检测到,但不是由733抗体检测到)参与肿瘤进展。这些结果表明,乙酰肝素酶表达在结肠癌发生过程中被诱导,并且在结肠腺瘤-癌进展过程中其加工、构象和定位受到严格调控。